Back to results
US 2006/0105999 A1Published application
Novel inhibitors of beta-lactamase
AssigneeMethylGene Inc.
InventorsJeffrey Besterman, Jubrail Rahil, Arkadii Vaisburg
Life of this patent
Estimating the term…
Abstract
The invention relates to bacterial antibiotic resistance and, in particular, to compositions and methods for overcoming bacterial antibiotic resistance. The invention provides novel β-lactamase inhibitors, which are structurally unrelated to the natural product and semi-synthetic β-lactamase inhibitors presently available, and which do not require β-lactam pharmacophore. The invention also provides pharmaceutical compositions and methods for inhibiting bacterial growth.
Claims32
A compound of the following formula:
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is phenyl or thien-2-yl, each optionally substituted;
- L is a covalent bond, —CH2O—, —C(O)—, or —C(═N—OCH3)—;
- and
- R5 is -halo or —OR10 wherein R10 is phenyl, pyridinyl, or quinolinyl, each optionally substituted,
- provided that when L is —CH2O—, R5 is not —F or p-nitrophenyl.
3 more elements
A compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is
- R3 is —H or —CO2R9, wherein R9 is -C1-C3-alkyl;
- R6 is —L1—A—(L2—B)s, wherein
- L1 is C0-C3-alkyl optionally mono- to per-halogenated;
- A is C3-C6-cycloalkyl, aryl, or heteroaryl;
- L2 is a covalent bond or (C0-C3-hydrocarbyl-X1-(C0-C3-hydrocarbyl), wherein X1 is —C(O)—, —NH—, —NH—C(O)—, —C(O)—NH—, or heteroaryl;
- B is —H, C3-C6-cycloalkyl, aryl, or heteroaryl;
- and
- s is 0 or 1;
- wherein when s is 0, (L2—B)s is —H or halo, and A and B are independently optionally substituted with 1-3 moieties independently selected from the group consisting of halo, —NO2, —CO2H, —CN, —C(O)—NH2, —SO2—NH2, or -C0-C3-hydrocarbyl-Y-(C1-C3-hydrocarbyl) wherein Y is a covalent bond, —O—C(O)—, —C(O)—, —O—, —S—, —SO2—, —C(O)—NH—, or —NH—C(O)—;
- and each alkyl moiety is optionally mono- to per-halogenated.
9 more elements
A compound of formula:
- or a pharmaceutically acceptable salt thereof, wherein
- R1 is
- optionally substituted with 1-3 moieties independently selected from the group consisting of —F, —Cl, —Br, —CO2H, —C(O)O—CH3, —CF3, —OCH3, —OCF3, -C1-C6 alkyl, —CN, —C(O)NH2, —S—CF3, —SO2CH3, —NO2, —CF3CF3, —SO2CF3, —SO2CF3CF3, and —SO2NH2;
- R6 is —L1—A—(L2—B)s, wherein
- L1 is C0-C3-alkyl optionally mono- to per-halogenated;
- A is C3-C6-Cycloalkyl, aryl, or heteroaryl;
- L2 is a covalent bond or (C0-C3-hydrocarbyl)-X1-(C0-C3-hydrocarbyl), wherein X1 is —C(O)—, —NH—, —NH—C(O)—, —C(O)—NH—, or heteroaryl;
- B is —H, C3-C6-cycloalkyl, aryl, or heteroaryl;
- and
- s is 0 or 1;
- wherein when s is 0, (L2—B)s is —H or halo, and A and B are independently optionally substituted with 1-3 moieties independently selected from the group consisting of halo, —CF3, —NO2, —CO2H, —CN, —C(O)—NH2, —SO2—NH2, or -C0-C3-hydrocarbyl-Y-(C1-C3-hydrocarbyl) wherein Y is a covalent bond, —O—C(O)—, —C(O)—, —O—, —S—, —SO2—, —C(O)—NH—, or —NH—C(O)—;
- and each alkyl moiety is optionally mono- to per-halogenated.
9 more elements
Dependencies are inferred from the claim text.